Compare Stocks → The Next Nvidia? (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:SVRANASDAQ:TFFP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsSVRASavara$4.70-2.3%$4.96$1.76▼$5.70$649.31M0.77849,580 shs684,874 shsTFFPTFF Pharmaceuticals$2.58-17.0%$6.17$2.51▼$21.25$7.83M1.2940,520 shs47,251 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%SVRASavara-2.29%-6.75%-2.08%-6.93%+161.11%TFFPTFF Pharmaceuticals-17.04%-26.70%-66.45%-46.03%-84.20%The Next Nvidia? (Ad)The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.4433 of 5 stars3.51.00.00.02.01.70.6TFFPTFF Pharmaceuticals1.7172 of 5 stars3.53.00.00.02.40.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/ASVRASavara3.00Buy$8.2074.47% UpsideTFFPTFF Pharmaceuticals3.00Buy$72.002,690.70% UpsideCurrent Analyst RatingsLatest TFFP, CLSN, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/28/2024TFFPTFF PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $44.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00SVRASavaraN/AN/AN/AN/A$1.04 per shareN/ATFFPTFF Pharmaceuticals$730K8.91N/AN/A$4.04 per share0.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ASVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$12.51N/AN/AN/A-2,897.95%-163.14%-144.77%5/9/2024 (Estimated)Latest TFFP, CLSN, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023TFFPTFF Pharmaceuticals-$2.00-$2.01-$0.01-$2.01$0.20 million$0.11 million3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52SVRASavara0.1915.6615.66TFFPTFF PharmaceuticalsN/A3.123.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%SVRASavara87.93%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%SVRASavara4.58%TFFPTFF Pharmaceuticals5.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableSVRASavaraN/A138.15 million131.82 millionOptionableTFFPTFF Pharmaceuticals192.52 million2.38 millionOptionableTFFP, CLSN, and SVRA HeadlinesSourceHeadlineTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99msn.com - April 17 at 11:27 PMTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation Powdermarkets.businessinsider.com - April 15 at 9:43 AMTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessionsglobenewswire.com - April 15 at 7:00 AMTFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - April 1 at 10:13 AMTFF Pharmaceuticals reports positive phase 2 trial resultsinvesting.com - March 29 at 11:52 PMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 29 at 8:50 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 4:05 PMTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programsglobenewswire.com - March 27 at 4:01 PMTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingglobenewswire.com - March 25 at 9:01 AMTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 22 at 3:11 PMTFF Pharmaceuticals, Inc. (TFFP)finance.yahoo.com - March 21 at 9:12 PMTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 20 at 12:00 PMTFF Pharmaceuticals Announces Update on Clinical Programsglobenewswire.com - March 20 at 9:03 AMTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024globenewswire.com - March 14 at 4:47 PMTff Pharmaceuticals Inc (TFFP)uk.investing.com - March 12 at 6:49 PMTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conferencefinance.yahoo.com - January 24 at 10:43 AMTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingfinance.yahoo.com - January 9 at 10:39 AMTFF Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 5 at 1:08 PMPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price Targetmarkets.businessinsider.com - December 21 at 8:22 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023investorplace.com - December 20 at 11:12 AMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACfinanznachrichten.de - December 19 at 8:56 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.